Brokers Set Expectations for OPKO Health, Inc.’s FY2024 Earnings (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for shares of OPKO Health in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst I. Bandyopadhyay now anticipates that the biotechnology company will post earnings per share of ($0.35) for the year, up from their prior estimate of ($0.36). The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. Zacks Research also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.12) EPS.

Other equities research analysts have also recently issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, April 3rd. Finally, Barrington Research reiterated an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Stock Up 3.3 %

NASDAQ OPK opened at $1.25 on Wednesday. The company has a market capitalization of $871.24 million, a price-to-earnings ratio of -5.00 and a beta of 1.82. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average is $1.07 and its two-hundred day moving average is $1.24. OPKO Health has a 1-year low of $0.85 and a 1-year high of $2.24.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). The business had revenue of $181.90 million for the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) EPS.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 1,500,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was purchased at an average price of $0.98 per share, for a total transaction of $1,470,000.00. Following the acquisition, the chief executive officer now owns 207,368,225 shares in the company, valued at $203,220,860.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 1,500,000 shares of OPKO Health stock in a transaction dated Wednesday, February 7th. The stock was purchased at an average cost of $0.98 per share, for a total transaction of $1,470,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 207,368,225 shares of the company’s stock, valued at $203,220,860.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard M. Krasno acquired 30,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the acquisition, the director now directly owns 103,333 shares in the company, valued at $102,299.67. The disclosure for this purchase can be found here. Insiders purchased a total of 4,630,000 shares of company stock valued at $4,422,700 in the last quarter. Insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

A number of institutional investors have recently modified their holdings of the business. State Street Corp raised its position in OPKO Health by 56.7% in the 1st quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock worth $95,250,000 after purchasing an additional 10,014,088 shares during the period. Millennium Management LLC grew its position in OPKO Health by 318.6% in the 2nd quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock valued at $18,698,000 after acquiring an additional 5,624,866 shares during the last quarter. Invesco Ltd. increased its holdings in shares of OPKO Health by 300.4% in the 3rd quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock valued at $8,263,000 after acquiring an additional 3,874,519 shares during the period. Renaissance Technologies LLC grew its position in shares of OPKO Health by 848.7% in the 2nd quarter. Renaissance Technologies LLC now owns 3,890,172 shares of the biotechnology company’s stock worth $9,842,000 after buying an additional 3,480,129 shares during the last quarter. Finally, Norges Bank purchased a new position in OPKO Health in the fourth quarter worth $4,042,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.